Key Takeaways

• Tesamorelin is a GHRH analogue, not recombinant GH. Its endocrine action begins by stimulating the pituitary rather than directly supplying growth hormone.
• GHRH acts primarily on pituitary somatotrophs. It binds the GHRH receptor, a G-protein-coupled receptor, and promotes intracellular signaling that supports GH synthesis and secretion.
• GH secretion is pulsatile. The growth-hormone axis is not simply an “on/off” pathway; pulse frequency and amplitude are regulated by interacting hypothalamic and peripheral signals.
• Somatostatin provides the major opposing hypothalamic signal. GHRH stimulates GH secretion, while somatostatin suppresses it.
• GH and IGF-1 form a feedback system. Rising GH and IGF-1 participate in negative feedback that helps prevent uncontrolled activation of the axis.
• IGF-1 is an important downstream endocrine mediator. Much of circulating IGF-1 is produced by the liver in response to GH, although peripheral tissues also produce IGF-1.
• Tesamorelin increases endogenous GH and IGF-1. Clinical pharmacodynamic data show increased GH secretion followed by increased IGF-1 and IGFBP-3.
• The endocrine response is not equivalent to administering GH itself. GHRH-analogue signaling interacts with the body’s existing regulatory architecture.
• Age, sleep, nutrition, metabolic state, sex hormones and other signals influence the axis. The same GHRH stimulus therefore occurs within a highly regulated physiological environment.

The Growth-Hormone Axis in One Diagram

At the same time, somatostatin inhibits GH secretion, while GH and IGF-1 contribute to negative feedback at the hypothalamic-pituitary level.

What Is GHRH?

Growth hormone-releasing hormone, or GHRH, is a hypothalamic peptide hormone that regulates the synthesis and secretion of growth hormone from somatotroph cells in the anterior pituitary.

It is therefore useful to think of GHRH as an upstream endocrine signal.

GHRH does not simply act as GH. Instead, it communicates with the pituitary’s somatotroph population and helps determine when and how much GH is released.

Modern reviews describe GHRH as one of the central regulators of the somatotropic axis, operating in opposition to somatostatin and in coordination with other neural and metabolic signals.

Where Tesamorelin Fits Into the Axis

Tesamorelin is a synthetic analogue of GHRH/GRF. Its endocrine pharmacology is therefore different from that of a molecule that directly replaces GH.

According to the FDA prescribing information, tesamorelin binds and stimulates human growth-hormone-releasing-factor receptors with similar potency to endogenous GRF under in-vitro conditions.

The same prescribing information describes GHRH as a hypothalamic peptide that acts on pituitary somatotrophs to stimulate synthesis and pulsatile release of endogenous GH.

This gives us a simple conceptual distinction:

The Pituitary Step: Somatotrophs and the GHRH Receptor

The anterior pituitary contains specialized GH-producing cells called somatotrophs.

GHRH binds to the GHRH receptor on these cells. The GHRH receptor belongs to the class B family of seven-transmembrane G-protein-coupled receptors.

Activation of this receptor stimulates intracellular signaling, prominently involving cyclic AMP and protein kinase A pathways, which contribute to GH gene transcription, synthesis and secretion.

The receptor also has an important role in somatotroph biology beyond an immediate secretory pulse. Research has linked GHRH signaling to somatotroph proliferation and cellular function.

Modern receptor reviews continue to describe the pituitary GHRH receptor as the principal mediator through which GHRH stimulates GH secretion.

Why GH Secretion Is Pulsatile

One of the most important concepts in endocrinology is that GH is not secreted at a constant rate.

Instead, circulating GH shows pronounced pulses separated by periods of relatively low concentrations.

These pulses emerge from the interaction between:

• GHRH stimulation;
• somatostatin inhibition;
• ghrelin and other secretagogues;
• sleep and circadian influences;
• metabolic status;
• sex steroids;
• age;
• nutritional state; and
• feedback from GH and IGF-1.

This is why a single random GH measurement can be difficult to interpret. A blood sample taken during a pulse can look very different from one obtained during a trough.

Classic human physiology research established the pulsatile nature of GH secretion and the opposing roles of GHRH and somatostatin. More recent reviews have expanded this model to include metabolic, neural and peripheral signals.

GHRH and Somatostatin: The Push-Pull System

A useful way to visualize the hypothalamic regulation of GH is as a push-pull system.

This means tesamorelin does not operate in an isolated biochemical vacuum. Its effect occurs within a pre-existing neuroendocrine control system.

What Happens After GH Is Released?

GH acts on a wide range of tissues through the growth hormone receptor.

Some GH effects are direct. Others occur through downstream production of IGF-1.

The liver is an important source of circulating IGF-1, although IGF-1 is also produced locally in peripheral tissues.

IGF-1 then acts through its own receptor to influence cellular growth, differentiation, metabolism and other biological processes.

Therefore, the axis is better represented as:

Current endocrine reviews emphasize that GH has both direct and IGF-1-mediated actions, and that GH signaling involves multiple intracellular pathways rather than a single downstream mechanism.

IGF-1 Is Not Simply “Another Name for GH”

GH and IGF-1 are closely connected but biologically distinct hormones.

GH is produced by pituitary somatotrophs. IGF-1 is produced in multiple tissues, with the liver contributing substantially to circulating concentrations.

GH receptor activation can stimulate hepatic IGF-1 production. IGF-1 then participates in many of the downstream biological effects traditionally associated with the somatotropic axis.

Importantly, IGF-1 also participates in negative feedback regulation of GH secretion. This creates a self-regulating endocrine loop rather than a simple linear pathway.

The Feedback Loop

The simplified diagram “GHRH → GH → IGF-1” is useful, but it is incomplete without feedback.

As GH and IGF-1 activity increases, feedback mechanisms reduce further stimulation of the axis. This occurs through effects at both hypothalamic and pituitary levels.

IGF-1 has been shown to inhibit GH gene transcription and secretion at the pituitary, while GH and IGF-1 also influence hypothalamic regulatory signals.

The result is a dynamic system that continually adjusts its output rather than producing an unlimited endocrine response.

What Tesamorelin Does to GH and IGF-1

The pharmacodynamic profile of tesamorelin fits this endocrine model.

FDA clinical pharmacology information states that tesamorelin stimulates GH secretion and subsequently increases IGF-1 and IGFBP-3 concentrations.

Clinical trials provide direct evidence for this effect. In a pooled analysis of two phase III studies involving 806 HIV-infected adults with excess abdominal fat, tesamorelin treatment increased mean IGF-1 by approximately 108 ng/mL compared with a small decrease in the placebo group at 26 weeks.

Another randomized clinical trial demonstrated increased overnight GH as well as significant increases in IGF-1 and IGF-1 z-scores during tesamorelin treatment.

These findings are important because they establish a pharmacodynamic chain rather than merely an association:

Tesamorelin Is Not Recombinant GH

This distinction is fundamental.

Recombinant human GH provides GH itself. Tesamorelin instead stimulates the pituitary’s endogenous GH system through a GHRH-like signal.

This does not mean that one approach is automatically superior. They are pharmacologically different strategies that interact with the GH axis at different points.

Why Pulsatility Matters

The physiological GH profile is characterized by pulses, and the biological consequences of GH depend partly on the pattern of exposure.

Sleep is one of the strongest physiological influences on GH secretion. Age is another major determinant. Sex steroids, nutritional state, obesity and metabolic signals also modify GH secretion.

Consequently, “higher GH” is an incomplete description of endocrine physiology.

A better set of questions is:

• How much GH is being secreted?
• When are the pulses occurring?
• How large are the pulses?
• How long does the signal persist?
• What happens to IGF-1?
• How does feedback modify subsequent secretion?

Reviews of the human GH/IGF-1 axis emphasize the major effects of age, obesity, gonadal function and sleep on GH secretion.

Age and the Somatotropic Axis

GH secretion changes substantially across the lifespan.

Healthy adults generally experience a decline in GH secretory activity with advancing age. This does not mean that the GH axis simply “turns off”; rather, pulse characteristics, secretion rates and responsiveness change over time.

Historical endocrine research estimated a substantial age-related decline in daily GH secretion, while modern research continues to examine how aging changes GHRH neurons, somatotroph function, feedback sensitivity and peripheral GH/IGF-1 signaling.

This is one reason the endocrine context of a GHRH analogue cannot be separated from age and physiological state.

Sleep Is an Endocrine Input, Not Just a Lifestyle Variable

GH secretion is strongly linked to sleep architecture, particularly deep sleep.

This is an important reminder that the GH axis is regulated by the nervous system. Hypothalamic neurons integrate signals related to circadian timing, sleep, energy balance and metabolic state before influencing pituitary hormone release.

In practical scientific terms, the endocrine response to a GHRH signal occurs within a system already influenced by sleep and circadian physiology.

Nutrition and Metabolic State Also Matter

GH secretion is influenced by nutritional status and metabolic signals.

Fasting, glucose availability, insulin, free fatty acids and other metabolic variables can alter GH secretion. Obesity is also associated with altered GH secretory dynamics.

This does not mean that GH is simply a “metabolic hormone.” It means the somatotropic axis is integrated with whole-body energy regulation.

Modern reviews describe this integration as a key feature of neuroendocrine control rather than an incidental effect.

Why GH and IGF-1 Should Be Interpreted Together

A single GH concentration can be misleading because secretion is pulsatile.

IGF-1 behaves differently. It has a longer circulating half-life and is therefore commonly used as a more stable biomarker of GH-axis activity than a random GH measurement.

However, IGF-1 is not a perfect surrogate for every biological action of GH. GH has direct tissue effects that do not require an intermediate IGF-1 step.

What Happens at the Cellular Level After GH Binds Its Receptor?

GH acts by binding the growth hormone receptor on target cells.

Receptor activation involves receptor dimerization and activation of associated Janus kinase 2 (JAK2), followed by phosphorylation of signaling proteins including STAT family transcription factors.

These pathways ultimately alter gene transcription and cellular processes involved in growth, metabolism and tissue function.

The molecular biology of GH signaling therefore extends well beyond the initial endocrine pulse.

Why the GH Axis Is More Complex Than “More GH = Better”

Endocrinology does not generally treat hormone concentrations as simple linear optimization targets.

The GH/IGF-1 axis operates within physiological ranges and feedback systems. Excessive or inappropriate activation can have consequences that are different from physiological replacement or restoration of deficient signaling.

Likewise, an increase in IGF-1 demonstrates pharmacodynamic activity but does not automatically establish a beneficial clinical outcome for every person or every purpose.

This distinction is especially important when discussing investigational peptide products.

What Clinical Tesamorelin Research Demonstrates

The clinical tesamorelin literature provides unusually clear evidence that a GHRH analogue can activate the somatotropic axis in humans.

What the Endocrine Evidence Does Not Prove

• An increase in IGF-1 does not automatically prove a clinical benefit for every population.
• Activation of the GH axis does not mean that tesamorelin is equivalent to administering GH directly.
• Physiological GH biology cannot be reduced to one blood-test value.
• Higher GH or IGF-1 is not inherently synonymous with better health.
• Findings from tesamorelin clinical trials in HIV-associated abdominal adiposity should not automatically be generalized to every population or every research use.
• The existence of a GHRH analogue does not eliminate the importance of somatostatin, feedback, sleep, age or metabolic state.

Statistics & Evidence Snapshot

Frequently Asked Questions

1. What does GHRH stand for?

GHRH stands for growth hormone-releasing hormone. It is a hypothalamic peptide that stimulates GH synthesis and secretion from pituitary somatotroph cells.

2. What is tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone/growth hormone-releasing factor. It stimulates the pituitary GHRH receptor and increases endogenous GH secretion.

3. Does tesamorelin contain growth hormone?

No. Tesamorelin is a GHRH analogue. Its primary endocrine action is to stimulate the pituitary to release endogenous GH rather than directly supplying GH itself.

4. What happens after GHRH reaches the pituitary?

GHRH binds to GHRH receptors on somatotroph cells, activating intracellular signaling that promotes GH synthesis and secretion.

5. What is the role of somatostatin?

Somatostatin is a major inhibitory regulator of GH secretion. The balance between GHRH stimulation and somatostatin inhibition contributes to the pulsatile pattern of GH release.

6. Why is GH secreted in pulses?

GH secretion is controlled by interacting hypothalamic and peripheral signals. GHRH, somatostatin, ghrelin, sleep, metabolic state, age and feedback from GH and IGF-1 all contribute to the timing and magnitude of GH pulses.

7. Why does tesamorelin increase IGF-1?

By stimulating GH secretion, tesamorelin activates the downstream GH/IGF-1 axis. GH stimulates IGF-1 production, particularly in the liver, although IGF-1 is also produced in peripheral tissues.

8. Is IGF-1 the same thing as GH?

No. GH and IGF-1 are different hormones with different sources, receptors and biological actions. They are linked through the somatotropic axis.

9. Can IGF-1 be used as a marker of GH-axis activity?

Yes. IGF-1 is often useful because it is more stable in circulation than the highly pulsatile GH concentration. However, IGF-1 does not capture every direct action of GH.

10. Does higher GH always mean better health?

No. Endocrine physiology depends on appropriate regulation, timing and tissue responsiveness. A pharmacodynamic increase in GH or IGF-1 should not automatically be interpreted as a universal health benefit.

11. Does age affect the GH axis?

Yes. GH secretory activity and pulse characteristics generally decline with age, while the regulation of GHRH, somatostatin and downstream signaling also changes.

12. Does sleep affect GH secretion?

Yes. Sleep, particularly deep sleep, is an important physiological regulator of GH secretion and contributes to the normal pulsatile pattern.

13. Is tesamorelin the same as recombinant human GH?

No. Recombinant GH supplies GH directly, whereas tesamorelin stimulates the endogenous GH system through the GHRH receptor.

14. Why is the GHRH receptor important?

It is the principal pituitary receptor through which GHRH stimulates somatotroph function. Activation initiates intracellular signaling involved in GH synthesis and secretion.

15. Is tesamorelin research only about the GH/IGF-1 axis?

The GH/IGF-1 axis is its core endocrine mechanism, but clinical research has investigated downstream physiological and body-composition effects as well. Those outcomes should be interpreted separately from the basic endocrine mechanism.

Related Articles

• Vietnam Peptides Knowledge Hub: Peptide Research & Education
• Peptide FAQ: Research, Storage & Usage Questions
• Tesamorelin Injection Pen: GHRH Peptide Research
• Tirzepatide Injection Pen: GLP-1/GIP Endocrine Signaling Research

Related Research Products

Related Research Plan

Scientific References

1. Update on regulation of GHRH and its actions on GH secretion in health and disease. Endocrine. PMID: 39838154. DOI: 10.1007/s11154-025-09943-y.
2. Central and peripheral regulation of the GH/IGF-1 axis: GHRH and beyond. Reviews in Endocrine and Metabolic Disorders. PMID: 39579280.
3. Signaling mechanism of growth hormone-releasing hormone receptor. PMID: 37717982. DOI: 10.1016/bs.vh.2023.06.004.
4. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. PMID: 39934495.
5. Neuroendocrine Regulation of Growth Hormone Secretion. Comprehensive Physiology. PMID: 27065166. DOI: 10.1002/cphy.c150002.
6. Physiological regulation of the human growth hormone-insulin-like growth factor type I axis. PMID: 9085516. DOI: 10.1093/sleep/19.suppl_10.s221.
7. Physiological role of somatostatin on growth hormone regulation in humans. PMID: 1976218. DOI: 10.1016/0026-0495(90)90207-S.
8. Molecular mechanism of growth hormone action. Annual Review of Physiology. PMID: 8815791. DOI: 10.1146/annurev.ph.58.030196.001155.
9. Mechanism of signaling by growth hormone receptor. Physiological Reviews. PMID: 8874495. DOI: 10.1152/physrev.1996.76.4.1089.
10. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 trials. PMID: 20554713. DOI: 10.1210/jc.2010-0490.
11. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation. PMID: 20101189.
12. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. PMID: 25038357. DOI: 10.1001/jama.2014.8334.
13. FDA. EGRIFTA SV / EGRIFTA WR Prescribing Information. Clinical pharmacology sections describing GHRH receptor activity, GH stimulation and subsequent increases in IGF-1 and IGFBP-3.
14. Growth hormone-releasing hormone receptor: signal transduction, gene expression, and physiological function in growth regulation. PMID: 8993403. DOI: 10.1111/j.1749-6632.1996.tb17483.x.
15. Molecular and cell biology of the growth hormone-releasing hormone receptor. PMID: 10429879. DOI: 10.1016/S1096-6374(99)80008-2.

Conclusion

Tesamorelin becomes much easier to understand when it is placed inside the normal architecture of the somatotropic axis.

The pathway begins upstream with GHRH signaling. GHRH activates receptors on pituitary somatotrophs, promoting synthesis and pulsatile release of endogenous GH. GH then acts directly on multiple tissues and stimulates production of IGF-1, particularly in the liver. GH and IGF-1 subsequently participate in feedback mechanisms that regulate the axis.

Tesamorelin is designed around this upstream endocrine mechanism. It is therefore fundamentally different from simply administering GH itself.

The clinical pharmacology of tesamorelin supports this model: treatment stimulates GH secretion and increases IGF-1 and IGFBP-3. Clinical studies have also documented increases in overnight GH and IGF-1.

But the most important endocrinology lesson is that the GH axis is a regulated network, not a single hormone switch.

That framework is the scientifically useful way to understand tesamorelin: not as a generic “fat-loss peptide,” but as a pharmacological signal acting within the human growth-hormone endocrine axis.